Council for europe portal
Language : en Search
Choose language

Actions on CEPs

GMP Non-Compliance

Information is now publicly available via the EudraGMDP data base.

The European Medicines Agency (EMA) has launched a new version of the EudraGMDP database which includes, among other changes, the publication of statements of non-compliance with Good Manufacturing Practice. Statements of non-compliance contain information on the nature of the non-compliance and the actions taken or proposed by the issuing authority in order to protect public health.

These statements aim to establish a coordinated and harmonized response by the network of European Union (EU) medicines regulators. Some non-compliance statements are the result of inspections carried out by the EDQM with the participation of EU/EEA national inspectorates. Any statement of GMP non-compliance that is related to a manufacturing site covered by a CEP application initiates the decision making process on the validity of the CEPs concerned by the EDQM, regardless of whether the EDQM has been involved in the inspection or not.

Information of a commercially or personally confidential nature is not made public. The decision on which information to make public is taken by the medicines regulatory authority in the EU Member State that adds the information to the database.

 

Read the updates on the last six months:

 

CEP Suspensions

 

 

a) As a result of an inspection of the manufacturing site(s)
 

Date Substance name CEP Number
20/08/18 Thiopental sodium and sodium carbonate CEP 2007-181

 

b) Due to a failure to fulfill the requirements of the CEP procedure:
 

Date

Substance name            

CEP Number

10/09/18 Meropenem trihydrate CEP 2015-148
24/08/18 Valsartan CEP 2014-162
17/08/18 Valsartan CEP 2013-159
17/08/18 Valsartan CEP 2016-069
09/07/18 Valsartan CEP 2010-072

 

c) Upon request from the holder, due to a temporary inability to produce the product under the approved conditions:
 

Date              

Substance name

CEP Number

07/08/18 Colchicine CEP 2002-062
04/06/18 Ascorbic acid CEP 2008-185

Return to top

 

CEP Withdrawals

 

a) As a result of an inspection of the manufacturing site(s):
 

Date             

Substance name

CEP Number

07/05/2018 Cefixime  CEP 2003-014
07/05/2018 Cefuroxime axetil CEP 2011-173

 

b) Due to a failure to fulfill the requirements of the CEP procedure with regards to updating the application and complying with GMP:
 

Date

Substance name

CEP Number

20/02/2018 Adrenaline tartrate  CEP 2014-362
20/02/2018 Noradrenaline tartrate CEP 2014-363

Return to top

 

Restoration of suspended CEP

 

Date

Substance name

CEP Number

14/08/18 Oxytetracycline hydrochloride  CEP 2001-125
08/06/18 Metronidazole CEP 2007-309
03/05/18 Simvastatin CEP 2011-323
03/05/18 Simvastatin CEP 2006-232
27/04/18 Simvastatin CEP 2006-091
27/04/18 Simvastatin CEP 2003-257
27/04/18 Simvastatin CEP 2007-155
24/04/18 Lansoprazole CEP 2008-204

Return to top

twitter facebook googleplus pinterest linkedin email